CG Oncology, Inc. Common stockCGONNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+59.0%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+59.0%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
4x
Strong expansion
Streak
4 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$116.64M+42.1%
2024$82.10M+79.5%
2023$45.75M+57.6%
2022$29.03M+58.5%
2021$18.32M-